Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Prevention of Neurosurgical Wound Infections (POWI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00915967
Recruitment Status : Completed
First Posted : June 8, 2009
Results First Posted : April 30, 2019
Last Update Posted : April 30, 2019
Sponsor:
Information provided by (Responsible Party):
Kim J. Burchiel, Oregon Health and Science University

Brief Summary:
The goal of this study is to determine whether injecting the antibiotic vancomycin directly into surgical wounds can decrease the rate of infection following implantation of neurosurgical devices.

Condition or disease Intervention/treatment Phase
Surgical Wound Infections Drug: Vancomycin Drug: Placebo (Saline Solution) Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 214 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Pilot Project: Prevention of Neurosurgical Wound Infections
Actual Study Start Date : May 13, 2009
Actual Primary Completion Date : December 19, 2014
Actual Study Completion Date : December 19, 2014

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Vancomycin
Subjects in the experimental group will receive Vancomycin injected directly into the wound pocket.
Drug: Vancomycin
Subjects randomized to the vancomycin group will receive an injection (up to 10 mL) of 5 mg/mL vancomycin administered directly into the wound with a blunt needle following watertight fascial closure.

Placebo Comparator: Saline
Subjects in the saline group will receive a Saline injection directly into the wound pocket.
Drug: Placebo (Saline Solution)
Subjects randomized to the saline group will receive an injection (up to 10 mL) of saline solution directly into the wound following watertight fascial closure.




Primary Outcome Measures :
  1. Incidence of Infection That Requires Removal of the Neurosurgical Device [ Time Frame: Six months post-operation ]
    The primary outcome was infection that required removal of the implanted device within 6 months of surgery. At our institution all patients with evidence of hardware infection have the entire stimulation/pump system removed. Subjects were either seen in clinic or reached by telephone more than 6 months after surgery and assessed for whether they had had infection requiring hardware removal or any superficial infection requiring additional post-operative antibiotics.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 99 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • deep brain stimulators (DBS)
  • spinal cord stimulators (SCS)
  • motor cortex stimulators (MCS)
  • vagus nerve stimulators (VNS)
  • peripheral nerve stimulators (PNS)

Exclusion Criteria:

  • allergies to vancomycin
  • immunocompromise or taking immunosuppressant drugs
  • currently taking aminoglycoside antibiotics, such as amikacin, gentamicin, neomycin, streptomycin or tobramycin
  • diagnosed renal failure
  • currently undergoing chemotherapy
  • pregnancy
  • non-english speakers
  • unable to return for follow-up, or unable to be contacted by telephone

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00915967


Locations
Layout table for location information
United States, Oregon
University Hospital, Oregon Health & Science University
Portland, Oregon, United States, 97239
Sponsors and Collaborators
Oregon Health and Science University
Investigators
Layout table for investigator information
Principal Investigator: Kim J Burchiel, MD Department of Neurological Surgery, Oregon Health & Science University
Principal Investigator: Valerie C Anderson, PhD, MCR Department of Neurological Surgery, Oregon Health & Science University
Principal Investigator: Stephen T Magill, PhD School of Medicine, Oregon Health & Science University
Publications:
Layout table for additonal information
Responsible Party: Kim J. Burchiel, Kim J. Burchiel, MD / John Raaf Professor and Chairman, Department of Neurological Surgery, Oregon Health and Science University
ClinicalTrials.gov Identifier: NCT00915967    
Other Study ID Numbers: IRB_5170
First Posted: June 8, 2009    Key Record Dates
Results First Posted: April 30, 2019
Last Update Posted: April 30, 2019
Last Verified: January 2019
Keywords provided by Kim J. Burchiel, Oregon Health and Science University:
Infection
Vancomycin
Neurosurgery
Stimulator
Pump
Deep Brain Stimulation
Intrathecal Pump
Additional relevant MeSH terms:
Layout table for MeSH terms
Infection
Communicable Diseases
Wound Infection
Surgical Wound Infection
Surgical Wound
Wounds and Injuries
Postoperative Complications
Pathologic Processes
Vancomycin
Anti-Bacterial Agents
Anti-Infective Agents